( ATLANTA--(BUSINESS WIRE)--Apr 5 2007 -...)MIV Therapeutics Announces Pivotal Test Results Further Validating,Company Stent Coatings Meet Critical FDA Fatigue Guidelines,Health

ATLANTA--(BUSINESS WIRE)--Apr 5, 2007 - MIV Therapeutics Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, today announced that a recent Company sponsored bench test confirmed that merging Biosync Scientific's certified bare metal stent platform, which MIVT recently acquired, with the Company's polymer-free drug delivery system met critical "FDA Draft Guidance for the Submission of Research and Marketing Applications for Interventional Cardiology Devices" requirements for in vitro mechanical fatigue testing.

The milestone bench test further validates the recent acquisition of India-based Biosync Scientific. The acquisition is expected to accelerate the commercialization of MIVT's proprietary next generation stent technology that targets an estimated $8 billion marketplace.

"We want to establish a high bench mark against which similar coating will have to be compared," said Mark Landy, President of MIV Therapeutics. "This test was a major validation of both our next generation drug eluting technology as well as our strategic move to acquire Biosync Scientific. It also reflects our mission to do everything possible in our commitment to bring to the market a safe, effective product, even if it means going beyond FDA mandates."

The rigorous bench test combined Biosync's GenX Cr-Co, a highly competitive bare metal stent platform that has already received CE Mark certification, with MIVT's HAp technology, a novel polymer-free drug-eluting stent coating. The test results proved that MIVT's microporous ceramic coating demonstrated exceptional durability with no failures, exceeding critical FDA longevity requirements.

The bench test successfully demonstrated the integrity of MIV's HAp and bare metal stents under mechanical fatigue failures for a minimum of 10 y
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care